EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL

Arthur Kaser  1     Bruce E. Sands  2     Marijana Protic  3     Laurent Peyrin-Biroulet  4     Zhantao Lin  3     Rebecca Hozak  3     Vipul Jairath  5     Hilde Carlier  3     Emily Hon  3     Monika Fischer  6    
1 University of Cambridge Gastroenterology and Hepatology, Cambridge, United Kingdom
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Eli Lilly and Company, Indianapolis, United States
4 University Hospital of Nancy, University of Lorraine, Vandoeuvre-les-Nancy, France
5 Western University & London Health Sciences Centre, London, Canada
6 Indiana University, Indianapolis, United States

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing